Clinical experience with calcipotriene has shown its efficacy in the treatment of psoriasis, both alone1-5 and in combination with other agents. This double-blind, placebo-controlled study was designed to provide clinical experience in the United States with once-daily treatment of plaque-type psoriasis with 0.005% calcipotriene ointment.
Patients and Methods.
Two hundred thirty-five otherwise healthy nonpregnant patients, aged 18 to 86 years (mean, 45.1 years), with stable plaque-type psoriasis covering 5% to 20% of skin surface and showing plaque elevation of at least 4 on a 9-point scale, were entered into a randomized, double-blind, clinical trial of 0.005% calcipotriene ointment applied once a day for 8 weeks. Scaling, erythema, plaque elevation, and physician's global assessment were scored on a 9-point scale. Patients were evaluated at baseline and at weeks 1, 2, 4, 6, and 8 of treatment (Figure 1).
Forty percent of patients treated with the active drug and 2.2%
Pariser DM, Pariser RJ, Breneman D, Lebwohl M, Kalb R, Moore J, Moss H, Parker C, Fiedler V. Calcipotriene Ointment Applied Once a Day for Psoriasis: A Double-Blind, Multicenter, Placebo-Controlled Study. Arch Dermatol. 1996;132(12):1527. doi:10.1001/archderm.1996.03890360121033